학술논문
비인두암의 방사선치료 결과
이용수 23
- 영문명
- Results of Radiotherapy in Nasopharyungeal Cancer
- 발행기관
- 대한방사선종양학회
- 저자명
- 신병철(Byung Chul Shin) 마선영(Sun Young Ma) 문창우(Chang Woo Moon) 염하용(Ha Yong Yum) 정태식(Tae Sig Jeung) 유명진(Myung Jin Yoo)
- 간행물 정보
- 『대한방사선종양학회지』제13권 제3호, 215~223쪽, 전체 9쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 1995.09.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Purpose : The aim of this study was to assess the effectiveness, survival rate and complication of radiation therapy in nasopharyngeal cancer.
Materials and Methods : From January 1980 to May 1989. Fifty patients who had nasoparyngeal carcinoma treated with curative radiation therapy at Kosin Medical Center were retrospectively studied. Thirty seven patients (74%) were treated with radiation therapy alone(Group Ⅰ) and 13 patients (26%) treated with combination chemotherapy and radiation(Group Ⅱ). Age distribution was 16-75 years (median: 45.8 years). In histologic type, squamous cell carcinoma was in 30 patients(60%), undifferentiated carcinoma in 17 patients(34%), and lymphoepithelioma in 3 patients(6%). According to AJCC staging system, 4 patients(8%) were in T₁, 13 patients (26%) in T₂. 20 patients (40%) in T₃, 13 patients(26%) in T₄ and 7 patients (14%) in T₀, 6 patients (12%) in N₁, 23 patients (46%) in N₂, 13 patients (28%) in N₃. Total radiation dose ranges were 5250-9200cGy(median: 7355cGy) in Group Ⅰ and 5360-8400cGy(median:6758Cgy) in Group Ⅱ. Radiotherapy on 4-6MV linear accelerator and/or 6-12MeV electron in boost radiation was given with conventional technique to 26 patients (52%), with hyperfractionation(115-120cGy/fr., 2times/day) to 16 patients (32%), with accelerated fractionation(160cGy/fr., 2times/day) to 8 patients(16%). In chemotherapy. 5 FU 1000mg daily for 5 consecutive days, pepleomycin 10mg on days 1 and 3, and cisplatin 100mg on day 1 were administered with 3weeks interval, total 1 to 3 cycles(average 1.8 cycles) prior to radiation therapy. Follow up duration was 6-140 months(mean: 58 months). Statistics was calculated with with Chi-square and Fisher's exact test.
Results : complete local control rates in Group Ⅰ and Ⅱ were 75.7%, 69.2%, Overall 5 year survival rates in Group Ⅰ and Ⅱ were 56.8%, 30.8%. Five year survival rates by histologic type in Group Ⅰand Ⅱ were 52.2%, 14.3% in squamous cell carcinoma and 54.5%, 50% in undifferentiated carcinoma.
Survival rates in Group Ⅰ were superior to those of Group Ⅱ though there were not statistically significant. In both group, survival rates seem to be increased according to increasing total dose of radiation up to 7500cGy, but not increased beyond it. There were not statistically significant differences in survival rates by age, stage, and radiation techniques in both group. Twenty four patients(48%) expericenced treatment failures. Complications were found in 12 patients(24%). The most common one was osteomyelitis(4 patients, 33.3%) involving mandible (3 patients) and maxilla(1 patient).
Conclusion : Chemotherapy in combination with radiotherapy was found to be not effective to nasopharyngeal cancer and the survival rate was also inferior to that of radiation alone group though it was statistically not significant due to small population in chemotherapy combined group.
목차
해당간행물 수록 논문
- 소아암의 방사선 치료후 발생한 이차 악성 고형 종양
- 식도암의 근치적 치료성적 및 예후인자
- Malignant Fibrous Histiocytoma of the Maxilla
- 6 MeV 전자선의 측정과 모의계산에 대한 연구
- Gingko Biloba Extract가 C3H 마우스 섬유육종의 저산소세포 분획에 미치는 영향
- 국소적으로 진행된 직장암에 대한 근치적 수술 단독 치료군과 수술후 보조적 방사선 및 항암화학요법 병행군의 치료결과 분석
- 조직 불균질성에 의한 고에너지 광자선의 선량변화
- 비인두암의 방사선치료 결과
- Wedge Factor의 임상적 응용
- Intraluminal High-Dose-Rate Brachytherapy for the Tumors of Gastrointestinal Tract
- 병기 Ⅲ 자궁경부암의 방사선치료 결과
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!